share_log

Today's biggest pre-market stock movers: vTv Therapeutics, Aehr Test Systems, Unique Fabricating and more

Benzinga Real-time News ·  Sep 24, 2021 08:15  · Movers

Gainers

  • $vTv Therapeutics Inc(VTVT.US)$rose 21.47% to $2.15 in pre-market trading after the company disclosed results of multiple ascending dose studies and a development plan for HPP737, an oral PDE4 inhibitor for the treatment of psoriasis.

  • $Aehr Test Systems(AEHR.US)$ rose 21.4% to $14.30 in pre-market trading after the company reported better-than-expected Q1 results. The company also said it sees FY21 revenue of $50 million.

  • $Unique Fabricating Inc(UFAB.US)$ rose 19.4% to $3.01 in pre-market trading. The company’s Director Patrick W Cavanagh acquired a total of 13333 shares at an average price of $2.25.

  • $Progress Software Corp(PRGS.US)$ rose 15.3% to $53.30 in pre-market trading as the company reported better-than-expected results for its third quarter and raised FY21 guidance. The company also announced the acquisition of privately held Kemp for $258 million in cash.

  • $Minerva Neurosciences Inc(NERV.US)$ rose 13.6% to $2.09 in pre-market trading after gaining around 10% on Thursday.

  • $The Cross-Harbour(Holdings)(00032.HK)$ shares rose 8.1% to $0.7995 in pre-market trading after gaining around 4% on Thursday.

  • $Novo Integrated Sciences Inc(NVOS.US)$ rose 7.3% to $2.06 in pre-market trading after declining around 8% on Thursday.

  • $Argo Blockchain(ARBK.US)$ rose 6.6% to $17.86 in pre-market trading. The company’s shares jumped around 12% on Thursday after the company priced its IPO at $15 per ADS.

  • $Huaneng Power(HNP.US)$ rose 6.3% to $23.30 in pre-market trading.

  • $ReWalk Robotics Ltd(RWLK.US)$ rose 5.5% to $2.29 in pre-market trading after jumping over 21% on Thursday.

  • $ChemoCentryx Inc(CCXI.US)$ rose 5.2% to $18.90 in pre-market trading after climbing around 5% in the previous session. ChemoCentryx, last month, reported a Q3 loss of $0.56 per share.

Losers

  • $HELBIZ INC(HLBZ.US)$ shares fell 12.1% to $20.21 in pre-market trading. Helbiz recently announced a partnership with Drover AI to integrate its PathPilot safety technology onto Helbiz e-scooters.

  • $InnSuites Hospitality Trust(IHT.US)$ fell 12.1% to $4.50 in pre-market trading after jumping over 45% on Thursday.

  • $Four Seasons Education(FEDU.US)$ fell 11.9% to $0.7310 in pre-market trading. Four Seasons Education shares climbed 43% on Thursday after the company announced board authorization to repurchase up to $15 million.

  • $Onconova Therapeutics Inc(ONTX.US)$ shares fell 11% to $4.55 in pre-market trading after the company reported a proposed public offering of common stock.

  • $MEDIROM Healthcare Technologies, Inc.(MRM.US)$ fell 9.8% to $11.54 in pre-market trading. MEDIROM Healthcare Technologies shares surged over 73% on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362 million.

  • $Amplitude Healthcare Acquisition Corp(AMHC.US)$ shares fell 7.4% to $13.30 in pre-market trading after climbing over 40% on Thursday. The company announced shareholders approved the business combination with Jasper Therapeutics.

  • $Senmiao Technology(AIHS.US)$ shares fell 7.4% to $0.7650 in pre-market trading after jumping over 16% on Thursday.

  • $Transcode Therapeutics(RNAZ.US)$ fell 6.7% to $3.75 in pre-market trading. TransCode Therapeutics shares surged 53% on Thursday after the company announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.

  • $Valneva SE(VALN.US)$ fell 6.5% to $31.69 in pre-market trading. Valneva said it commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K.

  • $Nike(NKE.US)$ fell 4.7% to $152.13 in pre-market trading. Nike reported better-than-expected earnings for its first quarter, while sales missed expectations. The company also lowered its sales forecast for the full year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment